NBTX Stock Analysis: Buy, Sell, or Hold?
NBTX - Nanobiotix S.A. American Depositary Shares
$38.39
-1.77 (-4.41%)
▼
5d:
-3.31%
30d:
-2.77%
90d:
+10.88%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Sep 29, 2026
Get Alerted When NBTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NBTX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: NBTX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NBTX is currently trading at $38.38, which is considered fair relative to its 30-day fair value range of $36.95 to $40.35. From a valuation perspective, the stock is trading at a discount (Forward PE: -130.9) compared to its historical average (178.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NBTX is in a uptrend. Immediate support is located at $35.00, while resistance sits at $40.88. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.93 (+17.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBTX is in a uptrend. Immediate support is located at $35.00, while resistance sits at $40.88. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.93 (+17.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$36.95 -
$40.35
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading below Wall St target ($44.93)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$36.95 -
$40.35
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$35.00
Resistance Level
$40.88
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-130.92
Wall Street Target
$44.93
(+17.1%)
Revenue Growth (YoY)
186.8%
Profit Margin
-73.5%
PE vs Historical
-130.9 vs 178.3
CHEAP
Share & Embed Analysis
Last updated: August 03, 2026 2:36 AM ET
Data refreshes hourly during market hours. Next update: 3:36 AM
Data refreshes hourly during market hours. Next update: 3:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
